Mylan NV (MYL)

16.11
0.43 2.60
NASDAQ : Health Technology
Prev Close 16.54
Open 16.33
Day Low/High 15.95 / 16.55
52 Wk Low/High 12.75 / 23.11
Volume 5.48M
Avg Volume 6.46M
Exchange NASDAQ
Shares Outstanding 516.95M
Market Cap 8.23B
P/E Ratio 132.75
Div & Yield N.A. (N.A)

Subscriber Comment of the Day (Part Deux)

Subscriber Comment of the Day (Part Deux): Neil S Allergan's stock is probably seeing additional weakness from two announcements: Mylan's biosmilar Botox partnership with Revance and the Food and Drug Administration's extension of the PDUFA date for...

Are Politics and Proxy Firms Killing Your Investment Returns?

Are Politics and Proxy Firms Killing Your Investment Returns?

Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.

Generic-Drug Stocks Are Looking Sickly

I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.

Staying Liquid

I missed very little and was better served at my "liquid" lunch meeting. Bitcoin was being bitcoin (+17%) with prices contrasting wildly by Exchanges -- a signpost that volatility will be with this commodity for some time. I have a double dose of Bo...

Mid-Afternoon Observations

Some mid afternoon observations:   * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...

Here's What's Up This A.M.

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside.   Co...

How to Trade the Saudi Arabia Anti-Corruption Moves: Market Recon

How to Trade the Saudi Arabia Anti-Corruption Moves: Market Recon

The Saudi Arabian economy needs to rebalance away from oil.

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.

Mylan Takes a Hit on Price Collusion Probe

Yesterday I reemphasized that Teva should be avoided. Today Mylan was hit by an apparent extension of a generic drug pricing collusion probe.  Mylan's shares have fallen by nearly seven precnet in the morning session.

Here's Why Teva Isn't My Cup of Tea

On Wednesday I explained why I would avoid Teva Pharmaceutical Industries : I know by the Comments Section that there has been a lot of bottom fishing in Teva (TEVA) . I had done a few hours of research on the company over the last months and passed...

Records for Wall Street, While FDA Approval Pushes Mylan to Top S&P 500

Records for Wall Street, While FDA Approval Pushes Mylan to Top S&P 500

The three major indexes closed at record highs, the Dow for its third day in a row, the Nasdaq its fourth, and the S&P 500 its fifth.

Only the Brave Trade Mylan

Only the Brave Trade Mylan

Risk is harder to gauge than a price target after a gap like the one we have on MYL.

Teva Still Hurts From Self-Inflicted Wounds

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.

Video: Jim Cramer on Netflix, Pepsi, Ford, Tesla, Mylan and Costco

Video: Jim Cramer on Netflix, Pepsi, Ford, Tesla, Mylan and Costco

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks.

Jim Cramer Reacts to Mylan's Multiple Sclerosis Drug

Jim Cramer Reacts to Mylan's Multiple Sclerosis Drug

Mylan scored FDA approval for a generic version of Teva Pharmaceuticals' multiple sclerosis drug, Copaxone.

Teva Still Hurts From Self-Inflicted Wounds

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.

A Look Back At Teva's History As Mylan Delivers the Drug-Maker Another Blow

A Look Back At Teva's History As Mylan Delivers the Drug-Maker Another Blow

The Israeli pharma company Teva has established a rich history since its founding in 1901. Can it continue to survive as it faces one challenge after another?

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.

Mylan's Copycat Drug OK Likely to Ding Allergan Shares

Mylan's drug approval announced this morning is a big negative for Teva Pharmaceutical Industries and likely will result in a $3 to $5 drop in Allergan's shares in the early going.

Will Allergan's Deal With Tribe Hold Up?

Will Allergan's Deal With Tribe Hold Up?

Answering questions from the biotech mailbag.

Trading Mylan: Look Out for This Key Level

Trading Mylan: Look Out for This Key Level

A retest of MYL's recent low is an important area.

How Activist Carl Icahn Became the 'Corporate Raider' We Know Today

How Activist Carl Icahn Became the 'Corporate Raider' We Know Today

"If you need a friend, get a dog."

Argus Cuts Mylan to Hold

Barcelona Terror Attack: Manhunt Is Underway

Barcelona Terror Attack: Manhunt Is Underway

13 people are dead and 100 injured in the terror attack at a popular tourist spot in Barcelona.

Midday Report: Target Leads Retail; Dow Returns Above 22,000

Midday Report: Target Leads Retail; Dow Returns Above 22,000

Strong quarterly performances from Target Corp. and Urban Outfitters Inc. inspired broader retail gains.

Citi Raises Mylan to Buy

Midday Report: Disney Weighs on Dow; North Korea Tensions Pull Markets Lower

Midday Report: Disney Weighs on Dow; North Korea Tensions Pull Markets Lower

Wall Street pulled lower mid-week on worries over rising tensions between the U.S. and North Korea.

Jim Cramer on Disney, Netflix, Wendy's, Priceline, Mylan, McCormick, Macy's, Kohl's and North Korea

Jim Cramer on Disney, Netflix, Wendy's, Priceline, Mylan, McCormick, Macy's, Kohl's and North Korea

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks.

Trader's Daily Notebook: Apple's Chart Looks Really Good

Trader's Daily Notebook: Apple's Chart Looks Really Good

I would look to begin trading it on the long side above $160.